Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India

References

• Department of AIDS Control, National AIDS Control Organization. Annual report 2012–2013. 2013. Ministry of Health & Family Welfare, Government of India.
   Google Scholar
• World Health Organization. 2012. WHO Res Net, including – Jordan MR, Barcarolo J, Parkin N, de Oliveira T, Bertagnolio S. WHO HIV drug resistance report 2012, WHO report. Geneva, Switzerland: WHO.
   Google Scholar
• Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M, etal. Five year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med. 2009; 151: 241–51.
   PubMed Web of Science ®Google Scholar
• Médecins Sans Frontières (MSF). Access campaign. Untangling the web of antiretroviral price reductions. 2013; Geneva, Switzerland: Médecins Sans Frontières. 16th ed.
   Google Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treatment and preventing HIV infection. 2013; Geneva: World Health Organization.
   Google Scholar
• Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, Saranchuk P, etal. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PloS ONE. 2012; 7: e40781.
   Google Scholar
• WHO. Antiretroviral Therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. 2010; Geneva: World Health Organization.
   Google Scholar
• 2010; India: Lorina Publications. Lorina Publications (India) Inc. Drug today – ready reckoner of current medical formulations, Vol. 1.
   Google Scholar
• World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. Available from: http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf [cited 4 June 2014].
   Google Scholar
• AIDS Clinical Trials Group. Division of AIDS table for grading the severity of adult and pediatric adverse events Version 1.0, 2004 Dec. Clarification 2009 Aug; Available from: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf [cited 30 April 2014].
   Google Scholar
• Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012; 26: 929–38.
   Google Scholar
• Pujades-RodrIguez M, Balkan S, Arnould L, Brinkhof MAW, Calmy A- for the AIDS Working Group of MSF. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010; 304: 303–12. [PubMed Abstract].
   Google Scholar
• Garone DB, Conradie K, Patten G, Cornell M, Goemaere E, Kunene J, etal. High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: a model of care in Khayelitsha, South Africa. South Afric J HIV Med. 2013; 14: 166–69.
   Web of Science ®Google Scholar
• Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, etal. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months’ antiretroviral therapy experience in Cameroon. J Int AIDS Soc. 2013; 16: 18004.
   Google Scholar
• Renaud-Théry AF, Duncombe C, Kerr S, Thierry S, Perriens J. Adult antiretroviral therapy in resource limited settings: a systematic review of first-line failure and attrition rates. Available from: http://www.who.int/hiv/topics/treatment/First_Line_ART_failure_RLS_metanalysis.pdf [cited 30 April 2014].
   Google Scholar
• Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008; 13(Suppl 2): 1–13. [PubMed Abstract].
   Google Scholar
• Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, etal. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004–2011. Clin Infect Dis. 2012; 54(Suppl 4): S245–9.
   Google Scholar
• Pujari SN, Makane A, Lodha A, Bele V, Joshi K. Short-term effectiveness and safety of third-line antiretroviral regimens among patients in Western India. J Acquir Immune Defic Syndr. 2014; 65: e82–4.
   Google Scholar
• Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, etal. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011; 58: 23–31.
   Google Scholar